10 Recruiting Relapsed/Refractory Multiple Myeloma Clinical Trials
Explore open interventional and observational research studies actively enrolling participants across the USA. Verify eligibility and contact site coordinators directly.
📍 Find Near Me by DistanceBrowse by State
Browse by Study Phase
Top Interventions for Relapsed/Refractory Multiple Myeloma
Top Recruiting Relapsed/Refractory Multiple Myeloma Studies
🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic
A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets
📍 Stanford University School of Med /ID# 242809 — Stanford, California
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
📍 University of Arkansas for Medical Sciences /ID# 243096 — Little Rock, Arkansas
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic
Cevostamab Following CAR T Cell Therapy for RRMM
📍 Hospital of the University of Pennsylvania — Philadelphia, Pennsylvania
View Study & Checklist ➔ 🟡 Not Yet Recruiting Phase2 💊 Investigational Drug / Biologic
A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma
📍 Johnston Hematology and Oncology of Clayton — Clayton, North Carolina
View Study & Checklist ➔ 🟢 Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
📍 University of Alabama At Birmingham Hospital — Birmingham, Alabama
View Study & Checklist ➔ 🟢 Recruiting Phase1 💊 Investigational Drug / Biologic
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
📍 University of Alabama at Birmingham — Birmingham, Alabama
View Study & Checklist ➔ 🟢 Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
📍 Research Site — Birmingham, Alabama
View Study & Checklist ➔ 🟢 Recruiting Phase1 💊 Investigational Drug / Biologic
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
📍 Standford Cancer Institute — Palo Alto, California
View Study & Checklist ➔